Thanks to their non-intervening nature, post-marketing drug utilization observation (DUO) studies reflect both the properties of the substance under investigation and doctors'treatment decisions, thus - in contrast with clinical trials - allowing the interactions of these two factors to be investigated.
A DUO study involving the administration of moclobemide to 9419 patients investigated the prescribing behavior of about two-thirds of all general practitioners and internists in Germany prescribing moclobemide during the study period.
The results obtained suggest that, on the whole, moclobemide is being prescribed knowledgeably and correctly for the treatment of the full spectrum of depressive disorders.
The management of these patients tended to adhere strictly to existing treatment recommendations while at the same time revealing a certain degree of latitude for treatment optimization.
This applies particularly to the utilization of the recommended dosage range, especially in severely depressed states, and the consistent, syndrome-based combination treatment with hypnotics/sedatives or neuroleptics in the respective patient groups indicated.
Potential interactions - though comparatively few are known for moclobemide - were taken into account in most cases.
The safety profile closely matches the experience gained from clinical trials.
Despite the large sample size involved there was no evidence of any hitherto unknown serious events. (...)
Mots-clés Pascal : Prescription médicale, Moclobémide, IMAO A, Antidépresseur, Psychotrope, Surveillance biologique, Méthodologie, Posologie, Etat dépressif, Trouble humeur, Homme
Mots-clés Pascal anglais : Medical prescription, Moclobemide, MAO A inhibitor, Antidepressant agent, Psychotropic, Biological monitoring, Methodology, Posology, Depression, Mood disorder, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0120565
Code Inist : 002B02B02. Création : 21/05/1997.